NEW YORK (GenomeWeb News) – CombiMatrix today said that Clarient has licensed rights to commercialize its DNAarray product portfolio.
The tests are based on array comparative genomic hybridization, and according to CombiMatrix, can provide physicians with "a comprehensive genomic profile of solid cancer tumors and blood-based cancers," which can help guide treatment.
The agreement provides Clarient, which is owned by GE Healthcare, with exclusive rights to commercialize oncology-related tests among commercial laboratories, based on certain minimum levels of sales. Financial and other terms of the deal were not disclosed.
"Our new collaboration calls for cooperative sales and marketing between our companies and also allows for an active relationship between the medical and scientific teams, which over time we believe will help to drive both the commercial adoption of DNAarray testing and the development of new companion diagnostics in the oncology space," R. Judd Jessup, president and CEO of Irvine, Calif.-based CombiMatrix, said in a statement.